Does growth hormone supplementation of in vitro fertilization/intracytoplasmic sperm injection improve cumulative live birth rates in women with poor embryonic development in the previous cycle?
Humans
Female
Sperm Injections, Intracytoplasmic
/ methods
Adult
Pregnancy
Retrospective Studies
Fertilization in Vitro
/ methods
Live Birth
/ epidemiology
Birth Rate
Embryonic Development
/ drug effects
Pregnancy Rate
China
/ epidemiology
Growth Hormone
/ administration & dosage
Human Growth Hormone
/ administration & dosage
Cohort Studies
Cumulative live birth rate
Embryo quality
Growth hormone
IVF
Propensity score matching
Journal
Reproductive biology and endocrinology : RB&E
ISSN: 1477-7827
Titre abrégé: Reprod Biol Endocrinol
Pays: England
ID NLM: 101153627
Informations de publication
Date de publication:
07 May 2024
07 May 2024
Historique:
received:
13
03
2024
accepted:
21
04
2024
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
7
5
2024
Statut:
epublish
Résumé
Growth hormone (GH) has been proposed as an adjunct in in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles, especially in women with poor ovarian response. However, it is unclear whether GH supplementation is effective in women with poor embryonic development in the previous IVF cycle. The aim of this study was to evaluate the effectiveness of GH supplementation in IVF/ICSI cycles in women with poor embryonic development in the previous cycle. This is a retrospective cohort study from a public fertility center in China, in which we performed propensity score-matching (PSM) for female age and AFC in a ratio of 1:1. We compared the cumulative live birth rate per started cycle, as well as a series of secondary outcomes. We included 3,043 women with poor embryonic development in the previous IVF/ICSI cycle, of which 1,326 had GH as adjuvant therapy and 1,717 had not. After PSM, there were 694 women in each group. After PSM, multivariate analyses showed the cumulative live birth rate to be significantly higher in the GH group than the control group [N = 694, 34.7% vs. N = 694, 27.5%, risk ratio (RR): 1.4 (95%CI: 1.1-1.8)]. Endometrial thickness, number of oocytes retrieved, number of embryos available, and number of good-quality embryos were significantly higher in the GH group compared to controls. Pregnancy outcomes in terms of birth weight, gestational age, fetal sex, preterm birth rate, and type of delivery were comparable. When we evaluated the impact of GH on different categories of female age, the observed benefit in the GH group did not appear to be significant. When we assessed the effect of GH in different AFC categories, the effect of GH was strongest in women with an AFC5-6 (32.2% versus 19.5%; RR 2.0; 95% CI 1.2-3.3). Women with poor embryonic quality in the previous IVF/ICSI cycles have higher rates of cumulative live birth with GH supplementation.
Sections du résumé
BACKGROUND
BACKGROUND
Growth hormone (GH) has been proposed as an adjunct in in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles, especially in women with poor ovarian response. However, it is unclear whether GH supplementation is effective in women with poor embryonic development in the previous IVF cycle. The aim of this study was to evaluate the effectiveness of GH supplementation in IVF/ICSI cycles in women with poor embryonic development in the previous cycle.
METHODS
METHODS
This is a retrospective cohort study from a public fertility center in China, in which we performed propensity score-matching (PSM) for female age and AFC in a ratio of 1:1. We compared the cumulative live birth rate per started cycle, as well as a series of secondary outcomes. We included 3,043 women with poor embryonic development in the previous IVF/ICSI cycle, of which 1,326 had GH as adjuvant therapy and 1,717 had not. After PSM, there were 694 women in each group.
RESULTS
RESULTS
After PSM, multivariate analyses showed the cumulative live birth rate to be significantly higher in the GH group than the control group [N = 694, 34.7% vs. N = 694, 27.5%, risk ratio (RR): 1.4 (95%CI: 1.1-1.8)]. Endometrial thickness, number of oocytes retrieved, number of embryos available, and number of good-quality embryos were significantly higher in the GH group compared to controls. Pregnancy outcomes in terms of birth weight, gestational age, fetal sex, preterm birth rate, and type of delivery were comparable. When we evaluated the impact of GH on different categories of female age, the observed benefit in the GH group did not appear to be significant. When we assessed the effect of GH in different AFC categories, the effect of GH was strongest in women with an AFC5-6 (32.2% versus 19.5%; RR 2.0; 95% CI 1.2-3.3).
CONCLUSIONS
CONCLUSIONS
Women with poor embryonic quality in the previous IVF/ICSI cycles have higher rates of cumulative live birth with GH supplementation.
Identifiants
pubmed: 38715065
doi: 10.1186/s12958-024-01223-9
pii: 10.1186/s12958-024-01223-9
doi:
Substances chimiques
Growth Hormone
9002-72-6
Human Growth Hormone
12629-01-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53Subventions
Organisme : the General Projects of Social Development in Shaanxi Province
ID : No. 2022SF-565
Informations de copyright
© 2024. The Author(s).
Références
Oron G, Son WY, Buckett W, Tulandi T, Holzer H. The association between embryo quality and perinatal outcome of singletons born after single embryo transfers: a pilot study. Human reproduction (Oxford, England). 2014;29(7):1444–51.
doi: 10.1093/humrep/deu079
pubmed: 24812313
Zhu J, Lian Y, Li M, Chen L, Liu P, Qiao J. Does IVF cleavage stage embryo quality affect pregnancy complications and neonatal outcomes in singleton gestations after double embryo transfers? J Assist Reprod Genet. 2014;31(12):1635–41.
doi: 10.1007/s10815-014-0351-8
pubmed: 25326318
pmcid: 4250469
Weall BM, Al-Samerria S, Conceicao J, Yovich JL, Almahbobi G. A direct action for GH in improvement of oocyte quality in poor-responder patients. Reproduction (Cambridge, England). 2015;149(2):147–54.
doi: 10.1530/REP-14-0494
pubmed: 25376626
Kobayashi J, Mizunuma H, Kikuchi N, Liu X, Andoh K, Abe Y, Yokota H, Yamada K, Ibuki Y, Hagiwara H. Morphological assessment of the effect of growth hormone on preantral follicles from 11-day-old mice in an in vitro culture system. Biochem Biophys Res Commun. 2000;268(1):36–41.
doi: 10.1006/bbrc.1999.2072
pubmed: 10652208
Hull KL, Harvey S. Growth hormone and reproduction: a review of endocrine and autocrine/paracrine interactions. International journal of endocrinology. 2014;2014:234014.
doi: 10.1155/2014/234014
pubmed: 25580121
pmcid: 4279787
Ipsa E, Cruzat VF, Kagize JN, Yovich JL, Keane KN. Growth Hormone and Insulin-Like Growth Factor Action in Reproductive Tissues. Front Endocrinol. 2019;10:777.
doi: 10.3389/fendo.2019.00777
Liu X, Bai H, Xie J, Shi J. Growth hormone co-treatment on controlled ovarian stimulation in normal ovarian response women can improve embryo quality. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2019;35(9):787–91.
doi: 10.1080/09513590.2019.1590545
pubmed: 30907187
Lattes K, Brassesco M, Gomez M, Checa MA. Low-dose growth hormone supplementation increases clinical pregnancy rate in poor responders undergoing in vitro fertilisation. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2015;31(7):565–8.
pubmed: 26193891
Hart RJ, Rombauts L, Norman RJ. Growth hormone in IVF cycles: any hope? Curr Opin Obstet Gynecol. 2017;29(3):119–25.
doi: 10.1097/GCO.0000000000000360
pubmed: 28306560
Sood A, Mohiyiddeen G, Ahmad G, Fitzgerald C, Watson A, Mohiyiddeen L. Growth hormone for in vitro fertilisation (IVF). Cochrane Database Syst Rev. 2021;11(11):Cd000099.
pubmed: 34808697
Li M, Xue X, Zhang S, Li W, Zhao X, Ren W, Shi J. Effects of triploidy incidence on clinical outcomes for IVF-ET cycles in different ovarian stimulation protocols. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2015;31(10):769–73.
doi: 10.3109/09513590.2015.1041907
pubmed: 26220642
Liu X, Shi W, Shi J. Natural cycle frozen-thawed embryo transfer in young women with regular menstrual cycles increases the live-birth rates compared with hormone replacement treatment: a retrospective cohort study. Fertil Steril. 2020;113(4):811–7.
doi: 10.1016/j.fertnstert.2019.11.023
pubmed: 32147171
Shi W, Xue X, Zhang S, Zhao W, Liu S, Zhou H, Wang M, Shi J. Perinatal and neonatal outcomes of 494 babies delivered from 972 vitrified embryo transfers. Fertil Steril. 2012;97(6):1338–42.
doi: 10.1016/j.fertnstert.2012.02.051
pubmed: 22464083
Drakopoulos P, Pluchino N, Bischof P, Cantero P, Meyer P, Chardonnens D. Effect of Growth Hormone on Endometrial Thickness and Fertility Outcome in the Treatment of Women with Panhypopituitarism: A Case Report. J Reprod Med. 2016;61(1–2):78–82.
pubmed: 26995894
Mason HD, Martikainen H, Beard RW, Anyaoku V, Franks S. Direct gonadotrophic effect of growth hormone on oestradiol production by human granulosa cells in vitro. J Endocrinol. 1990;126(3):R1-4.
doi: 10.1677/joe.0.126R001
pubmed: 2120380
Bachelot A, Monget P, Imbert-Bolloré P, Coshigano K, Kopchick JJ, Kelly PA, Binart N. Growth hormone is required for ovarian follicular growth. Endocrinology. 2002;143(10):4104–12.
doi: 10.1210/en.2002-220087
pubmed: 12239122
Li J, Chen Q, Wang J, Huang G, Ye H. Does growth hormone supplementation improve oocyte competence and IVF outcomes in patients with poor embryonic development? A randomized controlled trial. BMC Pregnancy Childbirth. 2020;20(1):310.
doi: 10.1186/s12884-020-03004-9
pubmed: 32434490
pmcid: 7238549
Ogino M, Tsubamoto H, Sakata K, Oohama N, Hayakawa H, Kojima T, Shigeta M, Shibahara H. Mitochondrial DNA copy number in cumulus cells is a strong predictor of obtaining good-quality embryos after IVF. J Assist Reprod Genet. 2016;33(3):367–71.
doi: 10.1007/s10815-015-0621-0
pubmed: 26749386
pmcid: 4785166
Taugourdeau A, Desquiret-Dumas V, Hamel JF, Chupin S, Boucret L, Ferré-L’Hotellier V, Bouet PE, Descamps P, Procaccio V, Reynier P, May-Panloup P. The mitochondrial DNA content of cumulus cells may help predict embryo implantation. J Assist Reprod Genet. 2019;36(2):223–8.
doi: 10.1007/s10815-018-1348-5
pubmed: 30362054
Gong Y, Luo S, Fan P, Zhu H, Li Y, Huang W. Growth hormone activates PI3K/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome. Reproductive biology and endocrinology : RB&E. 2020;18(1):121.
doi: 10.1186/s12958-020-00677-x
Yovich JL, Stanger JD. Growth hormone supplementation improves implantation and pregnancy productivity rates for poor-prognosis patients undertaking IVF. Reprod Biomed Online. 2010;21(1):37–49.
doi: 10.1016/j.rbmo.2010.03.013
pubmed: 20457541
Wang W, Cai J, Liu L, Xu Y, Liu Z, Chen J, Jiang X, Sun X, Ren J. Does the transfer of a poor quality embryo with a good quality embryo benefit poor prognosis patients? Reproductive biology and endocrinology : RB&E. 2020;18(1):97.
doi: 10.1186/s12958-020-00656-2